# Fecal Microbiota Transplant for Primary CDI

> **NCT03795233** · PHASE1,PHASE2 · TERMINATED · sponsor: **Boston Medical Center** · enrollment: 5 (actual)

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **BIOLOGICAL:** Fecal microbiota transplant G3 capsules
- **OTHER:** Oral Vancomycin alone

## Key facts

- **NCT ID:** NCT03795233
- **Lead sponsor:** Boston Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-23
- **Primary completion:** 2021-01-15
- **Final completion:** 2021-01-15
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study was terminated after a covid-related suspension and the unavailability of drug.
- **Last updated:** 2021-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03795233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03795233, "Fecal Microbiota Transplant for Primary CDI". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03795233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*